Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
42
CTXR Quote, Financials, Valuation and Earnings
Last price:
$1.26
Seasonality move
:
23.69%
Day range:
$1.12 - $1.27
52-week range:
$0.65 - $5.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.35x
Volume:
469.3K
Avg. volume:
565.1K
1-year change:
-65.66%
Market cap:
$23.1M
Revenue:
--
EPS (TTM):
-$5.09
Analysts' Opinion
-
Consensus RatingCitius Pharmaceuticals, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Citius Pharmaceuticals, Inc. has an estimated upside of 380% from its current price of $1.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -380% downside risk from its current price of $1.25.
Fair Value
-
According to the consensus of 2 analysts, Citius Pharmaceuticals, Inc. has 380% upside to fair value with a price target of $6.00 per share.
CTXR vs. S&P 500
-
Over the past 5 trading days, Citius Pharmaceuticals, Inc. has underperformed the S&P 500 by -10.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Citius Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Citius Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Citius Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Citius Pharmaceuticals, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Citius Pharmaceuticals, Inc. reported earnings per share of -$0.80.
Enterprise value:
21.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$205.9K
Return On Assets:
-36.05%
Net Income Margin (TTM):
--
Return On Equity:
-58.36%
Return On Invested Capital:
-57.79%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$190.6K | -$205.9K | -$205.9K | -$52.8K | -$41.4K | |
| Operating Income | -$34.2M | -$41.1M | -$41.1M | -$10.6M | -$8.8M | |
| EBITDA | -$34M | -$40.9M | -$40.9M | -$10.6M | -$8.7M | |
| Diluted EPS | -$5.16 | -$6.11 | -$4.96 | -$1.57 | -$0.80 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $116.9M | $50.8M | $41.1M | $28M | $24.6M | |
| Total Assets | $146.6M | $120.3M | $110.4M | $97.1M | $127.7M | |
| Current Liabilities | $3.6M | $4.5M | $5.8M | $4.2M | $51.8M | |
| Total Liabilities | $9.3M | $10M | $12.1M | $10.8M | $60.1M | |
| Total Equity | $137.3M | $110.3M | $98.3M | $86.3M | $67.6M | |
| Total Debt | $724.8K | $532.9K | $320K | $84.4K | $767K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.6M | -$29.1M | -$20.6M | -$8.4M | -$5.4M | |
| Cash From Investing | -- | -- | -$5M | -- | -- | |
| Cash From Financing | $13.8M | $13.7M | $13.8M | $13.7M | $11.5M | |
| Free Cash Flow | -$28.6M | -$29.1M | -$25.6M | -$8.4M | -$5.4M | |
CTXR
Sector
Market Cap
$23.1M
$28.8M
Price % of 52-Week High
21.01%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-73.04%
-1.32%
1-Year Price Total Return
-65.66%
-20.64%
Beta (5-Year)
1.509
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.28
200-day SMA
Sell
Level
$1.26
Bollinger Bands (100)
Sell
Level
1.14 - 1.5
Chaikin Money Flow
Sell
Level
-72.6M
20-day SMA
Buy
Level
$1.17
Relative Strength Index (RSI14)
Sell
Level
49.76
ADX Line
Buy
Level
21.2
Williams %R
Neutral
Level
-46.6903
50-day SMA
Sell
Level
$1.33
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
117.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.548)
Sell
CA Score
(Annual)
Level (-1.1265)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.5987)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Stock Forecast FAQ
In the current month, CTXR has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CTXR average analyst price target in the past 3 months is $6.00.
-
Where Will Citius Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Citius Pharmaceuticals, Inc. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Citius Pharmaceuticals, Inc.?
Analysts are divided on their view about Citius Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Citius Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Citius Pharmaceuticals, Inc.'s Price Target?
The price target for Citius Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $6.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CTXR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Citius Pharmaceuticals, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CTXR?
You can purchase shares of Citius Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Citius Pharmaceuticals, Inc. shares.
-
What Is The Citius Pharmaceuticals, Inc. Share Price Today?
Citius Pharmaceuticals, Inc. was last trading at $1.26 per share. This represents the most recent stock quote for Citius Pharmaceuticals, Inc.. Yesterday, Citius Pharmaceuticals, Inc. closed at $1.25 per share.
-
How To Buy Citius Pharmaceuticals, Inc. Stock Online?
In order to purchase Citius Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CTXR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CTXR
Sector
P/E ratio
--
23.71x
PEG ratio
--
-0.01x
P/B ratio
0.35x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
CTXR
Sector
Revenue growth
--
4.85%
Earnings growth
46.67%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.24
-$0.20
Profitability
CTXR
Sector
Profitability FY 2024
-$209.6K
$3.6M
Return on invested capital
-57.79%
-30.98%
Return on assets
-36.05%
-27.62%
Return on equity
-58.36%
-36.69%
Earnings Date
Last Earnings Date
Aug
12
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Nov
11
Balance Sheet
CTXR
Sector
Total cash
$6.1M
$27.2M
Short term investments
--
$25.7M
Total assets
$116.7M
$79.7M
Long term debt
$1.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 71.88% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 1.22% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.5% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
